Table 6 Adverse events reported by ≥ 2% of subjects in any treatment group (ITT population), n (%)
Latanoprost concentration (μg/mL) | ||||
|---|---|---|---|---|
50 | 75 | 100 | 125 | |
N | 71 | 70 | 72 | 69 |
Eye disorders | ||||
Abnormal sensation in eye | 3 (4.2) | 4 (5.7) | 7 (9.7) | 4 (5.8) |
Anterior chamber disorder NOS | 0 (0.0) | 2 (2.9) | 2 (2.8) | 1 (1.4) |
Conjunctival disorder NOS | 2 (2.8) | 1 (1.4) | 0 (0.0) | 0 (0.0) |
Conjunctival edema | 0 (0.0) | 2 (2.9) | 2 (2.8) | 0 (0.0) |
Conjunctival hyperemia | 12 (16.9) | 13 (18.6) | 15 (20.8) | 11 (15.9) |
Dry eye NEC | 1 (1.4) | 2 (2.9) | 4 (5.6) | 0 (0) |
Eye irritation | 5 (7.0) | 7 (10.0) | 6 (8.3) | 8 (11.6) |
Eye pain | 2 (2.8) | 6 (8.6) | 3 (4.2) | 4 (5.8) |
Eyelid disorder NOS | 0 (0.0) | 2 (2.9) | 0 (0.0) | 0 (0.0) |
Keratitis NEC | 2 (2.8) | 4 (5.7) | 3 (4.2) | 3 (4.3) |
Ocular hyperemia* | 5 (7.0) | 4 (5.7) | 5 (6.9) | 2 (2.9) |
Red eye | 3 (4.2) | 5 (7.1) | 6 (8.3) | 2 (2.9) |
Vision blurred | 1 (1.4) | 0 (0.0) | 2 (2.8) | 3 (4.3) |
Musculoskeletal, connective tissue and bone disorders | ||||
Arthralgia | 1 (1.4) | 0 (0.0) | 2 (2.8) | 1 (1.4) |
Nervous system disorders | ||||
Headache NOS | 4 (5.6) | 4 (5.7) | 3 (4.2) | 4 (5.8) |